Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Štefan Kukura Hospital in Michalovce
h-index: 12
Total citations: 599
Total papers: 33
Recent papers from Štefan Kukura Hospital in Michalovce
Primary G-CSF prophylaxis in sacituzumab govitecan–treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort
Supportive Care in Cancer · 2026
Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study
The Oncologist · 2026
Real-world survival outcomes with pembrolizumab plus chemotherapy in advanced triple-negative breast cancer: Multicenter evidence from Poland, the Czech Republic, and Slovakia.
Journal of Clinical Oncology · 2026
Prognostic value of baseline 18F-FDG PET/CT in first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer.
Journal of Clinical Oncology · 2026
Treatment-emergent thyroid disorders and outcomes of first-line pembrolizumab plus chemotherapy in metastatic triple-negative breast cancer: A real-world study.
Journal of Clinical Oncology · 2026
Radiotherapy in symptomatic metastatic triple-negative breast cancer treated with first-line pembrolizumab and chemotherapy: A multinational real-world study.
Journal of Clinical Oncology · 2026
Real-world outcomes of first-line pembrolizumab plus chemotherapy in metastatic triple-negative breast cancer with central nervous system metastases: A multicenter cohort from Poland, the Czech Republic, and Slovakia.
Journal of Clinical Oncology · 2026
Real-world effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients aged ≥65 years with metastatic triple-negative breast cancer.
Journal of Clinical Oncology · 2026
Ensuring the Quality and Performance of Functional Ceramic Powder Coatings: A Novel Approach Using Non‐Destructive Electrochemical Technique
Materials and Corrosion · 2026
Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort
Clinical & Translational Oncology · 2026
Abstract PS2-04-15: Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from a central European cohort
Clinical Cancer Research · 2026
Abstract PS5-03-08: Effectiveness of sacituzumab govitecan in later-line treatment of mTNBC: real-world evidence from Poland, Czech Republic, and Slovakia according to prior first-line pembrolizumab use
Clinical Cancer Research · 2026
Abstract PS1-05-12: Primary G-CSF Prophylaxis in Sacituzumab Govitecan-Treated mTNBC: Real-World Evidence from a Multinational Cohort
Clinical Cancer Research · 2026
Abstract PS5-03-04: Timing of final oncologist visit and systemic treatment use near the end of life in advanced triple-negative breast cancer: a multinational cohort study
Clinical Cancer Research · 2026
Abstract PS5-02-20: Treatment patterns and outcomes of sacituzumab govitecan in older versus younger patients with mTNBC: multinational real-world data
Clinical Cancer Research · 2026
Abstract PS1-08-01: Safety of Combining Radiotherapy With Sacituzumab Govitecan in Patients With Advanced Triple-Negative Breast Cancer: An International Multicenter Cohort Study
Clinical Cancer Research · 2026
Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe.
2026
Prospective evaluation of chemotherapy-induced dyslipidemia in early breast cancer: implications for cardiovascular risk
Frontiers in Oncology · 2026
Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study
The Breast · 2026
Age-specific measles immunity among health care personnel during an epidemic (2018) in Slovakia: Comparison with national immunological survey data
Preventive Medicine Reports · 2026